Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 5/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14184076 | 0.94 | RXRA (0.46) | RXRANR1H2NR1H3EPHX2TRPV4 | |
| SCHEMBL14214307 | 0.94 | RXRA (0.49) | RXRANR1H2NR1H3TRPV4RAF1 | |
| SCHEMBL14184077 | 0.87 | RXRA (0.46) | RXRANR1H2NR1H3EPHX2TRPV4 | |
| SCHEMBL14214374 | 0.85 | EPHX2 (0.41) | EPHX2TRPV4RAF1 | |
| SCHEMBL4905566 | 0.85 | RXRA (0.62) | RXRANR1H2NR1H3 | |
| SCHEMBL14214279 | 0.84 | RXRA (0.56) | RXRANR1H2NR1H3 | |
| SCHEMBL4899595 | 0.84 | RXRA (0.42) | RXRANR1H2NR1H3 | |
| Hydrochloric Acid SCHEMBL4904474 | 0.83 | RXRA (0.42) | RXRANR1H2NR1H3 | |
| SCHEMBL14184083 | 0.82 | RXRA (0.49) | RXRANR1H2NR1H3MET | |
| SCHEMBL14184079 | 0.81 | RXRA (0.48) | RXRANR1H2NR1H3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | RXRA 20/4885NR1H2 1/4885NR1H3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.